A Comparative Study of CD56 and Smooth Muscle Actin Expression in Basal and Squamous Cell Carcinomas.
Journal
The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
21
11
2023
pubmed:
20
11
2023
entrez:
20
11
2023
Statut:
ppublish
Résumé
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the 2 most common types of nonmelanoma skin tumors. Clinical or histopathological diagnostic challenges are encountered on occasion. CD56 and smooth muscle actin (SMA) are highly expressed in BCCs. We aimed to investigate the frequency of these markers, along with B-cell lymphoma 2 (Bcl-2) and Ki67. This study was conducted to propose a method that could possibly be of diagnostic value. One hundred twenty-eight BCC and 39 SCC cases were included in this study. CD56, SMA, Bcl-2, and Ki67 immunohistochemical stains were applied. Ninety-nine (77.3%) BCC and 6 (15.4%) SCC cases showed CD56 immunoreactivity. SMA expression was detected in 78.1% of BCC and 5.1% of SCC cases. CD56, SMA, and Bcl-2 expressions were significantly higher in BCC cases. The Ki67 proliferation index was found significantly higher in SCC cases. When basosquamous carcinoma cases were compared with SCC cases, a significant correlation between tumors and expression of CD56, SMA, and Bcl-2 were obtained. CD56 and SMA, in addition to Bcl-2, favor BCC. Ki67 should also be included in the panel to demonstrate the proliferative activity.
Identifiants
pubmed: 37982465
doi: 10.1097/DAD.0000000000002558
pii: 00000372-202312000-00004
doi:
Substances chimiques
Actins
0
Ki-67 Antigen
0
Proto-Oncogene Proteins c-bcl-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
816-819Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Gaballah MA, Ahmed R-A. Diagnostic value of CD10 and Bcl2 expression in distinguishing cutaneous basal cell carcinoma from squamous cell carcinoma and seborrheic keratosis. Pathol Res Pract. 2015;211:931–938.
Ramezani M, Mohamadzaheri E, Khazaei S, et al. Comparison of EMA,CEA, CD10 and bcl-2 biomarkers by immunohistochemistry in squamous cell carcinoma and basal cell carcinoma of the skin. Asian Pac J Cancer Prev. 2016;17:1379–1383.
García-de-la-Fuente MR, Santacana M, Valls J, et al. Cytokeratin profile of basal cell carcinomas according to the degree of sun exposure and to the anatomical localization. Am J Dermatopathol. 2018;40:342–348.
Ryu TH, Kye H, Choi JE, et al. Features causing confusion between basal cell carcinoma and squamous cell carcinoma in clinical diagnosis. Ann Dermatol. 2018;30:64.
Tan K-B, Tan S-H, Aw DC-W, et al. Simulators of squamous cell carcinoma of the skin: diagnostic challenges on small biopsies and clinicopathological correlation. J Skin Cancer. 2013;2013:1–10.
Sellheyer K. Basal cell carcinoma: cell of origin, cancer stem cell hypothesis and stem cell markers. Br J Dermatol. 2011;164:696–711.
Kirkham N, Aljefri K. Tumors and cysts of the epidermis. In: Elder DE, Elenitsas R, Rosenbach M, et al., eds Lever's Histopathology of the Skin. 11th ed. Philadelphia, PA: Lippincott Williams& Wilkins; 2015:1616–1642.
Beljaards RC, Kirtschig G, Boorsma DM. Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma. Dermatol Surg. 2008;34:1577–1579.
Tsukamoto H, Hayashibe K, Mishima Y, et al. The altered expression of α-smooth muscle actin in basal cell epithelioma and its surrounding stroma: with special reference to proliferating cell nuclear antigen expression and adenoid differentiation. Br J Dermatol. 1994;130:189–194.
Goto K. Under-recognized immunoexpression of “neuroendocrine markers” and “myoepithelial markers” in basal cell carcinomas: does it indicate true neuroendocrine and myoepithelial differentiation? J Cutan Pathol. 2017;44:991–993.
Terada T. Expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma: an immunohistochemical study of 66 consecutive cases. Med Oncol. 2013;30:444.
Yirmibeş S, Adım ŞB, Saraydaroğlu Ö. CD56 and smooth muscle actin immunoreactivity in basal cell carcinomas: are they indicators of differentiation or do they hold a diagnostic use? J Cutan Pathol. 2023;50:56–61.
Delehedde M, Cho SH, Sarkiss M, et al. Altered expression of bcl-2 family member proteins in nonmelanoma skin cancer. Cancer. 1999;85:1514–1522.
Swanson PE, Fitzpatrick MM, Ritter JH, et al. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens. J Cutan Pathol. 1998;25:153–159.
Messina J, Epstein EJ, Kossard S, et al. Basal cell carcinoma. In: Elder DE, Massi D, Scolyer RA, et al., eds WHO Classification of Skin Tumors. 4th ed. Lyon: IARC; 2018:26–34.
Chen-Tsai CP, Colome-Grimmer M, Wagner RF. Correlations among neural cell adhesion molecule, nerve growth factor, and its receptors, TrkA, TrkB, TrkC, and p75NGFR, in perineural invasion by basal cell and cutaneous squamous cell carcinomas. Dermatol Surg. 2004;30:1009–1016.
Lee M-W, Ahn S-J, Choi J-H, et al. Actin and calponin expression in basal cell carcinoma. Br J Dermatol. 2004;151:934–936.
Bozdogan O, Erkek E, Atasoy P, et al. Bcl-2-related proteins, alpha-smooth muscle actin and amyloid deposits in aggressive and non-aggressive basal cell carcinomas. Acta Derm Venereol. 2002;82:423–427.
Pilloni L, Bianco P, Manieli C, et al. Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas. Eur J Histochem. 2009;53:14–16.
Christian MM, Moy RL, Wagner RF, et al. A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma. Dermatol Surg. 2001;27:441–445.
Dicker T, Siller G, Saunders N. Molecular and cellular biology of basal cell carcinoma. Australas J Dermatol. 2002;43:241–246.
Garcia C, Poletti E, Crowson AN. Basosquamous carcinoma. J Am Acad Dermatol. 2009;60:137–143.
Fotiadou C, Apalla Z, Lazaridou E. Basosquamous carcinoma: a commentary. Cancers (Basel). 2021;13:6146.
Florescu D, Stepan AE, Mărgăritescu C, et al. Proliferative activity in basal cell carcinomas. Curr Health Sci J. 2018;44:55–60.
Zduniak K, Agrawal S, Symonowicz K, et al. The comparison of nuclear ubiquitous casein and cyclin-dependent kinases substrate (NUCKS) with Ki67 proliferation marker expression in common skin tumors. Polish J Pathol. 2014;1:48–54.
Healy E, Angus B, Lawrenck CM, et al. Prognostic value of Ki67 antigen expression in basal cell carcinomas. Br J Dermatol. 2006;133:737–741.
Al-Sader MH, Doyle E, Kay EW, et al. Proliferation indexes: a comparison between cutaneous basal and squamous cell carcinomas. J Clin Pathol. 1996;49:549–551.